|
|
|
| Meta-analysis of chemotherapy combined with cytokine-induced killer cells in the treatment of ovarian cancer |
| DUAN Wenli1 WANG Feng2 ZHANG Yan1 ZHOU Hang1 |
1.Department of Abdominal Oncology, Affiliated Hospital of Zunyi Medical University, Guizhou Province, Zunyi 563000,China;
2.School of Public Health, Zunyi Medical University, Guizhou Province, Zunyi 563000, China |
|
|
|
|
Abstract Objective To evaluate the effectiveness of chemotherapy combined with cytokine-Induced killer cells (CIK) in the treatment of ovarian cancer. Methods "Cytokine-induced killer cells" "CIK" "DC-CIK" "chemotherapy" "ovarian cance" as the retrieval words, the databases such as PubMed, Embase, the Cochrane Library, Medline, CNKI, VIP and WanFang Date were retrieved from the time of the database established to June 2017. Satisfactory randomized controlled clinical trial (RCT) or non-randomized concurrent control trial (NRCCT) were included. Meta-analysis was conducted by RevMan 5.3 software. Results Overall, 10 studies involving 788 patients with ovarian cancer were included. The results of Meta-analysis showed that, compared with chemotherapy alone group, the response rate (OR=1.93, 95%CI: 1.36-2.74, P=0.0002), disease control rate (OR=2.42, 95%CI: 1.46-4.02, P=0.0007), 1-year survival rate (OR=2.71, 95%CI:1.46-5.03, P=0.002), 2-year survival rate (OR=2.30, 95%CI: 1.31-4.04, P=0.004) and progression-free survival (MD=3.66, 95%CI: 1.31-6.01, P=0.002) in the chemotherapy combined with adoptive transfer of CIK group were improved. However, there were no significant differences between two groups in overall survival (MD=4.75, 95%CI: -3.58 -13.07, P=0.26). Conclusion For patients with ovarian cancer, the adoptive transfer of CIK can improve the efficacy of chemotherapy and delay progression, but it has no significant effect on the overall survival.
|
|
|
|
|
|
[1] 李若玢，欧阳媛，平文萍，等.血管生成抑制剂联合化疗治疗复发性卵巢癌疗效与安全性Meta分析[J].中国实用妇科与产科杂志，2017（3）：288-292.
[2] 倪志强，方艳秋，魏海峰，等. CIK细胞联合化疗治疗晚期卵巢癌临床观察[J].中国妇幼保健，2013，28（35）：5898-5901.
[3] 王志华. CIK细胞治疗癌症：国际临床试验的现状及展望[J].中国肿瘤生物治疗杂志，2013，20（2）：129-137.
[4] Guo Y，Han W. Cytokine-induced killer（CIK）cells：from basic research to clinicaltranslation[J].Chin J Cancer，2015， 34：6.
[5] Mesiano G，Todorovic M，Gammaitoni L，et al. Cytokine-induced killer（CIK）cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors [J]. Expert Opin Biol Ther，2012，12（6）：673-684.
[6] 刘建平.非随机研究的系f统评价方法（一）[J].中国循证医学杂志，2001，1（4）：239-243.
[7] 郝晓园，王新梅，王灵芝.CIK联合顺铂化疗治疗卵巢癌患者的临床疗效[J].医学综述，2017，23（8）：1652-1655.
[8] 史磊，张智慧，张国耀.化疗联合CIK细胞治疗卵巢癌的临床观察[J].中国实用医药，2016，11（24）：181-182.
[9] 张晓兰.细胞因子诱导的杀伤细胞联合TC方案治疗晚期卵巢癌的疗效及对生活质量和免疫功能的影响[J].中国老年学，2015，35（17）：4906-4908.
[10] 高翔，刘永军，李晓丹，等.细胞因子诱导杀伤细胞联合多西他赛、卡铂治疗晚期卵巢癌的疗效及安全性[J].山东医药，2015（5）：82-84.
[11] 李希，欧庆样.树突细胞一细胞因子诱导杀伤细胞免疫联合化疗治疗卵巢癌的临床效果[J].中国医药，2016， 11（6）：877-881.
[12] 王文翔，范文强，董学彩，等. DC-CIK细胞免疫治疗联合化疗对卵巢癌免疫功能的影响[J].山西医科大学学报，2014，45（12）：1193-1196.
[13] 王焱，刘岩，刘璞嘉. DC-CIK细胞免疫治疗配合化疗与单纯化疗治疗卵巢癌的疗效比较[J].中国实用医药，2016（6）：192-193.
[14] 张旭. DC-CIK联合化疗对晚期卵巢癌预后的影响[D].郑州：郑州大学，2016.
[15] 汪霖，马文青，陈永强，等. DC-CIK细胞免疫治疗联合化疗对中晚期卵巢上皮细胞癌患者免疫功能的影响[J].徐州医学院学报，2016，36（8）：509-513.
[16] 黄啸，蔡树模，汤洁，等.综合性治疗复发性卵巢上皮性癌的疗效及预后分析[J].中华妇产科杂志，2004，39（9）：602-605.
[17] Liu J，Li H，Cao S，et al. Maintenance therapy with autologous cytokineinduced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment. [J]. J Immunother，2014，37：115-122.
[18] Schmidtwolf IG，Lefterova P，Johnston V，et al. Sensitivity ofmultidrug-resistant tumor cell lines to immunologic effector cells. [J]. Cellular Immunology，1996，169（1）：85.
[19] Zhao Q，Zhang H，Li Y，et al. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro [J]. J Exp Clin Cancer Res，2010，29：118.
[20] 林菜梅，罗泽民，李勇.吉西他滨联合顺铂方案治疗复发卵巢癌的疗效观察[J].现代诊断与治疗，2015，26（14）：3180-3181.
[21] 于津浦，任秀宝，张澎，等.恶性实体瘤患者自体CIK细胞的体外大量扩增与生物学指标检测[J].中国肿瘤生物治疗杂志，2011，8（3）：215-216. |
|
|
|
